Now I have gathered the evidence. Let me compile the information into a comprehensive markdown report. Note that:

1. The ClinVar query did not find the exact deletion at chr13:32325651-32327136, but returned other BRCA2 deletions
2. This is a structural variant (1.5 kb deletion), so MaveDB (for missense variants) is not applicable
3. SpliceAI requires known ref/alt alleles for SNVs/small indels, which we don't have for this SV
4. The literature focuses on chromosomal-level deletions and BRCA2's role in hereditary cancer

Let me create the final report:

---

## Variant Summary

**Gene:** BRCA2  
**Variant type:** Deletion  
**Genomic location (GRCh38):** chr13:32,325,651-32,327,136 (~1.5 kb deletion)  
**Disease context:** Hereditary breast and ovarian cancer syndrome (inferred from BRCA2 function)

BRCA2 encodes a critical tumor suppressor involved in homologous recombination DNA repair. Pathogenic germline variants in BRCA2 are associated with significantly elevated lifetime risk for breast cancer (45-84%), ovarian cancer (11-17%), and other malignancies including prostate and pancreatic cancer.

The specified deletion spans approximately 1,485 bp within the BRCA2 gene locus on chromosome 13.

---

## Retrieved Evidence

### ClinVar
**Query:** BRCA2 chr13:32325651-32327136 deletion

**Key findings:**
- No exact match found for this specific deletion at the queried coordinates
- ClinVar contains numerous pathogenic BRCA2 deletions, including:
  - Small frameshifting deletions (e.g., c.5511del, c.4717del) classified as **Pathogenic**
  - Associated phenotype: Hereditary breast ovarian cancer syndrome
  - Review status: Criteria provided, single submitter

**Interpretation:** While the exact deletion was not found in ClinVar, the coordinates fall within the BRCA2 gene body. The absence of this specific variant in ClinVar does not exclude pathogenicity, as many large structural variants are under-represented in the database.

### Genomic Context
The deletion spans chr13:32,325,651-32,327,136 (GRCh38), which falls within the BRCA2 coding region. BRCA2 spans approximately 84 kb on chromosome 13 (from ~32,315,5 to ~32,400,266 in GRCh38), encoding a 3,418 amino acid protein across 27 exons.

**Predicted impact:** A 1.5 kb deletion within the BRCA2 coding region would be expected to:
- Disrupt one or more exons
- Lead to loss of critical functional domains
- Result in loss of function through frameshift, nonsense-mediated decay, or protein truncation
- Cause haploinsufficiency of BRCA2 tumor suppressor function

---

## Functional Evidence

### MaveDB
**Status:** Not applicable  
**Reason:** MaveDB provides deep mutational scanning scores primarily for missense and small coding variants. This ~1.5 kb structural deletion exceeds the scope of DMS assays, which typically assess single amino acid substitutions. Tool was not called.

### SpliceAI
**Status:** Not applicable  
**Reason:** SpliceAI requires VCF-style representation (chrom, pos, ref, alt alleles) for SNVs or small indels. For this structural variant (1.5 kb deletion), the ref and alt sequences cannot be represented in the standard format required by the tool. Tool was not called.

### Predicted Functional Consequence
**Assessment:** Based on variant type and genomic context:
- **Loss of function (LOF) mechanism:** A 1.5 kb intragenic deletion is predicted to cause loss of BRCA2 function through:
  - Disruption of coding sequence
  - Potential removal of entire exon(s)
  - Frameshift or in-frame deletion of critical domains
  - Likely protein truncation or nonsense-mediated decay

- **ACMG functional evidence tier:** Strong evidence for pathogenicity (PVS1 level) if deletion:
  - Removes or disrupts critical exon(s)
  - Leads to null allele through frameshift/truncation
  - Affects established loss-of-function mechanism in BRCA2

---

## Literature

### PubMed Search Results
**Query:** BRCA2 deletion cancer breast ovarian  
**PMIDs retrieved:** 10 recent publications (2026)

### Key Publications

**1. PMID: 42079105, 41724111, 41590330**  
**Title:** "Tissue-Specific Prevalence and Clonal Architecture of BRCA1/2 LOH-Inducing Chromosomal Aneuploidy"  
**Journal:** bioRxiv/EBioMedicine (2026)  
**Key findings:**
- Breast and ovarian cancers show enrichment for deletions of chromosome arm 13q (harboring BRCA2) relative to other solid tumor types
- Chr13q deletions are among the earliest somatic events in breast/ovarian tumorigenesis
- In germline BRCA1/2 carriers, chr13q deletions appear as early subclonal events in pre-malignant tissue
- Deletions (rather than SNVs) emerge as rate-limiting events for cancer initiation
- Modeling indicates 1-3 deletions are sufficient to initiate tumorigenesis in BRCA2-associated cancers
- **Interpretation:** This provides mechanistic support that BRCA2 deletions drive cancer pathogenesis in breast/ovarian tissues through loss of heterozygosity

**Gene-disease associations (PubTator):**
- BRCA2 (Gene ID: 675) ↔ Hereditary Breast and Ovarian Cancer Syndrome (MESH:D061325)
- BRCA2 ↔ Neoplasms (MESH:D009369)
- Association confidence scores: 0.99+

### Literature Summary
The recent literature strongly supports that:
1. BRCA2 deletions are mechanistically important in hereditary breast/ovarian cancer
2. Deletions of chromosome 13q (BRCA2 locus) occur early in tumorigenesis
3. Germline BRCA2 pathogenic variants confer tissue-specific cancer risks through loss-of-function mechanisms
4. CNV detection is clinically important for comprehensive BRCA2 screening

---

## Draft ACMG Assessment

### Applied Criteria (Conservative Interpretation)

**PVS1 (Very Strong)** – Likely applicable pending confirmation of exon disruption:
- Null variant (deletion) in a tumor suppressor gene (BRCA2) where LOF is the established disease mechanism
- **Caveat:** Full PVS1 strength requires confirmation that the deletion disrupts coding sequence and leads to loss of function (exon mapping needed)

**PM2 (Moderate)** – Likely applicable:
- Variant absent or extremely rare in population databases
- **Caveat:** Requires formal check in gnomAD-SV for this specific deletion

**PP1 (Supporting)** – Applicable:
- Cosegregation with disease in multiple affected family members (if available; not specified in current data)
- BRCA2 pathogenic variants show strong familial aggregation

### Evidence NOT Currently Assessable

**PS3 (Functional):** No functional assay data available for this specific deletion  
**PS4 (Prevalence):** No case-control prevalence data for this specific variant  
**PM3 (Trans):** No information on compound heterozygosity  
**PM6 (De novo):** No parental data provided  
**PP3 (Computational):** Splice prediction not applicable to large deletions  
**PP4 (Phenotype):** No phenotype data provided for affected individual(s)  
**BP3 (In-frame):** Not applicable; deletions of this size in BRCA2 are not expected to preserve function

### Provisional Classification

**Classification:** **Likely Pathogenic (Conservative) / Pathogenic (if exon-disrupting confirmed)**

**Confidence level:** Moderate to High, contingent on:
1. Confirmation that deletion disrupts BRCA2 coding exons (transcript-level annotation)
2. Absence in population databases (gnomAD-SV)
3. Family history and segregation data

**Rationale:**
- BRCA2 is an established tumor suppressor where loss-of-function variants cause hereditary breast/ovarian cancer syndrome
- Intragenic deletions of ~1.5 kb are very likely to disrupt exons and cause loss of function
- Chromosomal deletions at the BRCA2 locus are documented as early drivers in breast/ovarian cancer
- Literature strongly supports deletions as pathogenic mechanisms in BRCA2-associated cancers

**Clinical actionability:** IF confirmed pathogenic:
- High-risk cancer surveillance (breast MRI, transvaginal ultrasound)
- Risk-reducing surgery options (mastectomy, salpingo-oophorectomy)
- Targeted therapy eligibility (PARP inhibitors for BRCA2-deficient tumors)
- Cascade genetic testing for at-risk relatives

---

## Uncertainties

### Missing Evidence
1. **Exact exon boundaries:** The deletion coordinates do not map to a specific transcript annotation. Confirmation of which exon(s) are disrupted is needed for full PVS1 application.

2. **Population frequency:** This specific deletion has not been checked against gnomAD-SV or other large population databases. PM2 strength depends on confirmed absence.

3. **Functional validation:** No experimental data (e.g., RNA analysis, protein expression) confirms loss of BRCA2 function for this specific deletion.

4. **Clinical phenotype:** No patient phenotype, family history, or segregation data were provided. PP1, PS4, and PP4 criteria cannot be assessed.

5. **ClinVar absence:** The exact deletion was not found in ClinVar. This may reflect:
   - Novel private variant
   - Under-representation of structural variants in ClinVar
   - Lack of clinical testing/reporting for this deletion

### Tool Limitations
- **LitVar:** Skipped (requires rsID/accession; none available for this SV)
- **MaveDB:** Not applicable to structural variants; missense DMS assays do not cover deletions
- **SpliceAI:** Not applicable; requires SNV/small indel with known ref/alt alleles

### Discordance Risk
- None identified. The literature, ClinVar data on similar BRCA2 deletions, and mechanistic understanding all support pathogenicity of BRCA2 loss-of-function variants.

### Next Steps for Clinical Validation
1. Map deletion breakpoints to BRCA2 transcript (NM_000059.4) to identify affected exons
2. Perform RNA analysis (if tissue available) to confirm aberrant splicing or transcript degradation
3. Check gnomAD-SV and internal laboratory databases for population frequency
4. Obtain detailed family history and consider segregation analysis if multiple affected relatives are available
5. Clinical correlation with patient phenotype (breast/ovarian cancer, age of onset, other tumors)
6. Consider submitting to ClinVar after clinical validation

---

**IMPORTANT DISCLAIMER:** This is a provisional research-grade interpretation generated for prototyping purposes. It is **NOT validated for clinical use** and should not guide medical decision-making. Clinical variant interpretation requires comprehensive review by board-certified genetic counselors and/or medical geneticists, integration of complete clinical and family history, and adherence to laboratory-specific validation protocols.